EXEL: Expanding franchises, clinical innovation, and AI-driven efficiency fuel growth and market leadership
Key priorities include expanding product franchises in RCC and NETs, with CABOMETYX and zanzalintinib driving growth through new indications and robust clinical development. Market share gains, disciplined R&D spending, and broad AI adoption support strong financial and operational outlooks.Based o…